Study Finds Radium-223 Effective in Prostate Cancer Treatment Independently of Docetaxel Use

Study Finds Radium-223 Effective in Prostate Cancer Treatment Independently of Docetaxel Use
shutterstock_223018186A recent study titled “Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial”, published in The Lancet Oncology journal, has concluded that radium-223 dichloride (Xofigo), a radiopharmaceutical drug for prostate cancer treatment, is effective independently of previous chemotherapy treatment. After promising results from the ALSYMCA trial, Ra223 was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Now, the same researchers who conducted the previous trial designed a prespecified subgroup analysis from ALSYMPCA in order to understand the effect of previous docetaxel use on the efficacy and safety of radium-223. Robert B.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *